Qyuns Therapeutics Co., Ltd. (HKG:2509)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
19.38
+0.47 (2.49%)
At close: Mar 27, 2026
Market Cap4.35B +180.0%
Revenue (ttm)897.99M +408.2%
Net Income342.13M
EPS1.57
Shares Out224.57M
PE Ratio12.35
Forward PE16.98
Dividendn/a
Ex-Dividend Daten/a
Volume322,800
Average Volume150,047
Open18.91
Previous Close18.91
Day's Range18.32 - 19.53
52-Week Range7.80 - 36.50
Beta3.91
RSI56.44
Earnings DateMar 27, 2026

About Qyuns Therapeutics

Qyuns Therapeutics Co., Ltd., a clinical-stage biotech company, engages in the research and development of biologic therapies for autoimmune and allergic diseases in the People’s Republic of China. Its lead product candidates include QX002N, an interleukin (IL)-17A inhibitor, which is in Phase III clinical trial for the treatment of ankylosing spondylitis; and QX005N, a monoclonal antibody (mAb) blocking IL-4Ra that is in Phase III clinical trial for treating prurigo nodularis. The company also develops QX001S, which is an IL-12/L-23p49 inhibit... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 337
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2509
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements